120 related articles for article (PubMed ID: 28623781)
1. Inhibition activities of catechol diether based non-nucleoside inhibitors against the HIV reverse transcriptase variants: Insights from molecular docking and ONIOM calculations.
Samanta PN; Das KK
J Mol Graph Model; 2017 Aug; 75():294-305. PubMed ID: 28623781
[TBL] [Abstract][Full Text] [Related]
2. Torsional flexibility of undecorated catechol diether compound as potent NNRTI targeting HIV-1 reverse transcriptase.
Somboon T; Saparpakorn P; Hannongbua S
J Mol Graph Model; 2019 Jan; 86():286-297. PubMed ID: 30445408
[TBL] [Abstract][Full Text] [Related]
3. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
4. A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method.
Srivab P; Hannongbua S
ChemMedChem; 2008 May; 3(5):803-11. PubMed ID: 18338369
[TBL] [Abstract][Full Text] [Related]
5. Prediction of binding modes and affinities of 4-substituted-2,3,5,6-tetrafluorobenzenesulfonamide inhibitors to the carbonic anhydrase receptor by docking and ONIOM calculations.
Samanta PN; Das KK
J Mol Graph Model; 2016 Jan; 63():38-48. PubMed ID: 26619075
[TBL] [Abstract][Full Text] [Related]
6. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
7. Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise.
Hollander K; Chan AH; Frey KM; Hunker O; Ippolito JA; Spasov KA; Yeh YJ; Jorgensen WL; Ho YC; Anderson KS
Protein Sci; 2023 Dec; 32(12):e4814. PubMed ID: 37861472
[TBL] [Abstract][Full Text] [Related]
8. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
9. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
10. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
Carlsson J; Boukharta L; Aqvist J
J Med Chem; 2008 May; 51(9):2648-56. PubMed ID: 18410085
[TBL] [Abstract][Full Text] [Related]
11. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
[TBL] [Abstract][Full Text] [Related]
12. An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones.
Massarotti A; Coluccia A
J Mol Graph Model; 2016 Jan; 63():49-56. PubMed ID: 26650686
[TBL] [Abstract][Full Text] [Related]
13. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study.
Ercan S; Şenyiğit B; Şenses Y
J Biomol Struct Dyn; 2020 Feb; 38(2):573-580. PubMed ID: 31787027
[TBL] [Abstract][Full Text] [Related]
15. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
Treesuwan W; Hannongbua S
J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
[TBL] [Abstract][Full Text] [Related]
16. Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.
Saparpakorn P; Hannongbua S; Rognan D
SAR QSAR Environ Res; 2006 Apr; 17(2):183-94. PubMed ID: 16644557
[TBL] [Abstract][Full Text] [Related]
17. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
Lavecchia A; Costi R; Artico M; Miele G; Novellino E; Bergamini A; Crespan E; Maga G; Di Santo R
ChemMedChem; 2006 Dec; 1(12):1379-90. PubMed ID: 17089434
[TBL] [Abstract][Full Text] [Related]
18. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
[TBL] [Abstract][Full Text] [Related]
19. Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis.
Nizami B; Sydow D; Wolber G; Honarparvar B
Mol Biosyst; 2016 Oct; 12(11):3385-3395. PubMed ID: 27722739
[TBL] [Abstract][Full Text] [Related]
20. Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Titmuss SJ; Keller PA; Griffith R
Bioorg Med Chem; 1999 Jun; 7(6):1163-70. PubMed ID: 10428388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
